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The R2* measurement is recently gaining more acceptance as a clinical tool for monitoring iron concentration in thalassemia patients.1-3 The 
measurement can be conveniently performed on vari-
ous organs, such as the heart, liver or pancreas.4-7 Liver 
iron provides considerable information about total body 
iron stores and risk of iron-mediated complications.8-11 
Furthermore, R2* measurements also have the benefit 
of enabling the monitoring of the efficacy of the chelator 
agents whose efficacies on various organs are different.12-15 
The measurement can be divided into two parts: 
magnetic resonance (MR) acquisition and post-pro-
cessing analysis. Currently, the MR acquisition part is, 
well established in the clinical arena due to its robust-
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BaCKgROunD anD OBjECtIVES: mri-r2* has been accepted as a clinical tool for monitoring iron overload 
in thalassemia patients, especially for monitoring liver iron concentration (LiC). the most optimal and practical 
method of analysis however, is still open to further investigations. our objective was to investigate intra- and 
intersite observer variability of the pixel-wise method for liver r2* analysis in thalassemia patients using a mono-
exponential with a constant offset model.
patIEntS anD mEthODS: We performed 88 liver r2* measurements on 72 thalassemia major patients. a 
single breath-hold multi-echo gradient-echo sequence was acquired and analyzed at both the reference (rEf) 
and local (LoC) sites. the analysis defined the region of interest in the whole liver parenchyma, excluding the 
great vessels, and were reported as median values. 
RESuLtS: the r2* values from the rEf and LoC were statistically comparable for all comparisons. the intrasite 
and intersite observer variation were 0.75% (less than 0.9%) and 2.5%, respectively, both of which are compa-
rable to previous reports, but substantially lower than conventional region-based approaches. 
COnCLuSIOn: the low variation of the r2* also yielded excellent variation in the tabulated hepatic iron 
content. however, caution is required when comparing the results to different implementation methods and 
appropriate evaluation and validation of methodology for any new scan site is essential before its clinical use.
ness and can be scanned within a single breath-hold 
time.3,16 On the other hand, the analysis part involves 
various implementation methods. The differences may 
vary from calculation approaches, fitting models, or 
region of interest (ROI) selections.3 In general, there 
are two main calculation approaches: the region-based 
(RB) and pixel-wise (PW) methods,3,4,17 which can 
be analyzed on the single breath-hold images. The RB 
method begins with the averaging of each echo signal 
using a defined ROI and then fitting it to the exponen-
tial models. The PW method, on the other hand, fits 
the decay signal point by point over the whole liver and 
then averages the R2* values from the defined ROI. The 
RB method is a fast and robust technique, which is less 
original research report liVer r2* analYSiS
Hematol Oncol Stem Cell Ther 5(2)     Second Quarter 2012 hemoncstem.edmgr.com92
susceptible to respiratory motion, but it cannot provide 
the distribution pattern of R2* values in the liver. The 
PW method can overcome this limitation, but is more 
computationally intensive. In terms of fitting meth-
odologies, there are three accepted models for fitting 
the decay curves: the single-exponential (S-EXP), 
mono-exponential with constant offset (C-EXP), and 
bi-exponential (BI-EXP) models.3,4,17,18 The S-EXP 
model can be implemented with or without truncating 
the plateau part of the signal from the fitting (trun-
cation model). Finally, the ROI can be defined into 
two separate strategies as from partial or whole liver 
parenchyma.19 Previously, Positano et al20 investigated 
all such the differences on simulated data as well as 
on thalassemia patients and found that using median 
R2* calculated by the PW approach with the C-EXP 
model on the whole liver ROIs yielded the lowest in-
tra- and interobserver variations. However, there was 
some limitation since this study is performed only on-
site with custom automatic segmentation software for 
ROI generation.
Determination of liver iron concentration (LIC) 
has long been recognized as a standard monitoring 
in transfusion-dependent thalassaemia (TDT) pa-
tients who receive regular blood transfusions.21 Until 
recently it has been shown that the MRI approach 
for LIC measurement is also critically important in 
nontransfusion-dependent thalassaemia (NTDT) pa-
tients who show a weaker correlation between serum 
ferritin (SF) and LIC. Therefore, SF might not be able 
to predict the level of liver siderosis and guides iron 
chelation practice as it does in TDT.11 Moreover, us-
ing a non-invasive approach by MRI measurement can 
reduce undesirable complications and uncertainty re-
lated to standard liver biopsy. Although such an MRI 
measurement has been available by means of a stan-
dard service provider such as Ferriscan (Resonance 
Health Limited and Resonance Health Analysis 
Services Pty Limited, Claremont, Australia) in many 
developed countries, this essential monitoring remains 
limited to only a few thalassaemia patients, especially 
in the Far East where the cost of imaging and data in-
terpretation is still unaffordable by most patients.22 To 
provide accessibility to more affordable new technol-
ogy to under-funded thalassaemia patients in a setting 
where resources are limited such as Thailand, we have 
established the North-South collaboration between 
Mahidol University, Bangkok and the University of 
Southern California, Los Angeles, California, United 
States. Our local software designed to determine car-
diac T2* has been established and validated as report-
ed previously.3 In this report, we describe our further 
evaluation of thesoftware on the determination of LIC 
using MRI-R2*. We investigated intersite variation of 
the reference site (Children’s Hospital Los Angeles, 
California, United States) and our institute (Siriraj 
Hospital, Bangkok, Thailand) using manually defined 
ROI and independently generated analysis tools.
patIEntS anD mEthODS
Eighty-eight liver R2* measurements were performed 
on 72 transfusion-dependent thalassemia (TDT) pa-
tients (32 males and 40 females, mean [SD] age 18.0 
[6.9] years) who received regular transfusion and iron 
chelation therapy since ≥10 years old and had serum 
ferritin levels more than 1000 ng/mL. Patients with 
a contraindication to MR (such as pacemakers and 
claustrophobia) and an inability to comply with the 
instruction were excluded from the study. Approval of 
the study was obtained from the Institutional Review 
Board of Faculty of Medicine, Siriraj Hospital, 
Mahidol University.
The study was conducted on a 1.5T Philips Achieva 
XR Quasar Dual Gradient system (Philips Medical 
Systems, the Netherlands) using a five-element car-
diac phased-array coil. Each patient was scanned at a 
mid-hepatic slice using a multi-echo fast gradient-re-
called-echo sequence acquired within a single breath-
hold time.5 Imaging parameters were a repetition time 
(TR) of 80 ms, 20 echo times (1.07-16.30 ms with 
0.80 ms increments), a flip angle of 20 degrees, a slice 
thickness of 10 mm, a matrix of 128×256 pixels, and 
a field of view (FOV) of 40 cm, which yielded a vox-
el size of 3.1×1.6×10 mm3. In this study, hence, the 
maximum practical measurable R2* due to the limita-
tion of MR acquisition was 1308 Hz, which is a recip-
rocal of the minimum TE employed, divided by 1.4.3,20 
The acquired images were analyzed locally (LOC) 
and also transferred in DICOM format to process at 
the reference (REF) sites. All R2* analyses were per-
formed independently at both sites using individual-
ly-developed custom-written software implemented 
in MATLAB software (The MathWork, Natick, 
Massachusetts, United States).3 The PW method us-
ing the C-EXP model was employed for such calcula-
tion at both sites. The raw and R2* parametric images 
were then employed to manually define a large ROI of 
the whole liver parenchyma excluding the major blood 
vessels.3,17 Two MR technologists independently per-
formed the analysis at the local site (intrasite observer) 
and data were also compared to the result from the 
reference site (intersite observer). The R2* results 
were reported as the median of the data inside the 
defined ROI and the hepatic iron content (HIC) was 
original research reportliVer r2* analYSiS
Hematol Oncol Stem Cell Ther 5(2)     Second Quarter 2012 hemoncstem.edmgr.com 93
tabulated from the linear relationship with the R2* ac-
cording to the expression of (3): 
HIC (mg/g dw) = 0.0254×R2* (Hz) + 0.202 
According to the maximum practical measurable 
R2* in this study, the maximum measurable HIC in 
this study, hence, was about 33.40 mg/g dry weight.
 All statistical analyses were evaluated using the 
MATLAB Statistics Toolbox. A Bland-Altman plot 
was used to analyze the agreement between the two dif-
ferent R2* data sets. The coefficient of variation (CV) 
was used as the quantitative analysis of the closeness 
of the agreement. The CV was calculated from the 
standard deviation of the difference between the two 
data sets, then divided by their mean and presented as 
a percentage. The paired t test was selected to evaluate 
the difference between the data. A P value less than .05 
was consider to be significant. 
RESuLtS
An example of liver images with corresponding tabu-
lated HIC map overlaid with defined ROIs (the blue 
line) from the whole liver parenchyma are shown in 
Figure 1. These data were obtained from a thalassemia 
patient who had severe iron concentration in the liver. 
In this study, the mean R2* values from the ref-
erence and local sites were 695±463 and 700±463 
Hz, respectively (P=not significant). The differences 
between the intra- and interobservers at the local site 
were also not significant. Sixteen patients were exclud-
ed from the validation because their liver R2* was out 
of the measurable range (R2* >1308 Hz).
The Band-Altman plots of the R2* and HIC values 
from intra- and intersite observers of the measurable 
data range are shown in Figure 2. The correspond-
ing bias, 95% CI, and the CV of these variations are 
presented in Table 1. The intrasite variation in the 
measurable range had a small bias (0.39 Hz) and CV 
(0.83%). The intersite variation was also remarkably 
low with R2* bias less than 5 Hz and CV of 2.5% 
as shown in Figure 2 and in the last row of Table 1. 
Thus, the variation of the tabulated HIC from the in-
tersite variability in the study had a bias lower than 
0.12 mg/g dry weight and CV of 2.2%. The linear 
correlation of R2* between the two sites was in very 
good agreement with a coefficient of determination of 
0.998. However, if all patient data were included for 
the validation, the intersite variation would have a bias 
of about 8 Hz and 4.5% of CV with a coefficient of 
determination of 0.986. In summary, in this study, the 
intrasite CV of the R2* data in the measurable range 
was less than 0.9%, while it was only about 2.5% for 
the intersite with a low bias for all comparisons (less 
than 1 and 5 Hz for intra- and intersite variation, 
respectively). Such a low variation of the R2* yield-
ed also an excellent variation in the tabulated HIC, 
which had a similar low bias and CVs. 
DISCuSSIOn
At present, the MRI measurements of R2 and R2* 
have essentially replaced conventional liver biopsy for 
hepatic iron quantification in thalassemia patients, 
due to its accuracy and ease of use. Suitable R2* im-
ages can be obtained using a single breath hold multi-
echo gradient-echo sequence that has become standard 
on all three major MRI platforms. Some disagreement 
still exists regarding the optimal analysis methods,3 
although PW assessment with constant offset com-
Figure 1. example liver images from the first (a) and fourth (B) echoes and 
corresponding hepatic iron content (HiC) map (C) overlaid with rOis (the blue line) 
obtained from a thalassemia patient. The color-map scale bar for hepatic iron content 
(HiC) map is displayed at the bottom in mg /g dry weight.
Figure 2. Bland-altman plots of intra- and intersite reproducibility of the r2* and tabulated 
hepatic iron content (HiC) (the top and bottom row, respectively). The left column presents 
the intrasite observer variation while the intersite observer is on the right.
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pensation has the largest validation against biopsy and 
against computer simulations.20,23 The analysis in this 
study, hence, employed such a method to further inves-
tigate the intra- and intersite variation and found that 
the method also provided comparable bias and varia-
tions as described in Positano’s report,20 even when us-
ing only a manually defined ROI instead of automatic 
liver segmentation. Intrasite variation was about 0.75%, 
which is comparable to the previously reported 0.85%, 
but substantially lower than 3.7% or 4.4% from the 
conventional RB approach.20,24 Intersite observer vari-
ability was about 2.5%, which is comparable to the same 
method reported by Positano et al at 2.9%, but lower 
than the 5.6% from the RB approach employed in clini-
cal practice.20,24 The variability in this study arises from 
differences in tracing liver boundaries and differences in 
software implementation of the fitting routines; given 
the small overall error, these differences must be insig-
nificant. While automatic segmentation may facilitate 
the speed of image interpretation, reproducibility was 
similar to manual boundaries.20,23
Although the observer variation of the liver R2* 
analysis from the conventional RB approach was al-
ready in acceptable ranges, a two-fold reduction in 
variability may be important at high R2* values, for 
assessing interval change, and for clinical trial design; 
a two-fold lowering of variability translates to a four-
fold decrease in patient accrual targets. However, 
caution must be used when comparing across stud-
ies. The lower intersite variation found in the present 
work might be due to high liver R2* values (723±480 
Hz) which may have lower variability on a percentage 
basis than measurements on less heavily loaded pa-
tients. Prior reports have also reported T2* variabil-
ity, which will tend to emphasize errors at lower iron 
concentrations. We also excluded patients whose R2* 
were greater than the measurable range (R2* >1308 
Hz), which reduced the variation from 4.5% to 2.5%. 
Such high variations due to the out-of-range data 
have been reported in previous studies as well.3,20 The 
exclusion of such data, nevertheless, does not effect 
the clinical data range because it is more than two 
times the cut-off point (R2*=588 Hz or HIC=15 
mg/g dry weight) of what is considered to be severe 
iron overload in the liver.25
Even though the study demonstrated a low R2* 
analysis, caution is still required when comparing the 
results to different implementation methods. Various 
factors may affect such comparisons. First, if we com-
pared the PW to RB approach, the result will be com-
parable for the clinical range, but will be systematically 
underestimated by the RB method in the normal range 
(R2* <50 Hz).20 Second, in our study we employed 
the C-EXP model so when comparing our result to 
another study using the BI-EXP model, the result is 
still fully comparable, but our R2* result will be under-
estimated by about 333 Hz over the whole R2* range 
when compared to the S-EXP model.20 Finally, when 
comparing our result from the whole liver ROI to a 
partial one, as in the conventional method, the varia-
tion will be higher due to the sampling error on the 
latter method, which is due to the heterogeneity of live 
iron deposition.19, 20
The study may have some limitations. There are few 
patients who have liver iron overload in the borderline 
or normal ranges so the observer variation reported 
in this study relied heavily on patients with iron over-
load. More patients recruited in these borderline iron 
overload and normal LIC regions will help to better 
represent observer variation from the whole ranges. 
Furthermore, a basic semi-automatic liver segmenta-
tion should also help to further optimize the operator 
interactions and furthermore make the result more con-
sistent for follow-up studies. 
In conclusion, the intrasite CV of the liver R2* data 
in the measurable range was less than 0.9% in our study, 
while only about 2.5% for the intersite CV with a low 
bias for all comparisons. Such a low variation of the R2* 
yielded excellent variation in the tabulated HIC. Our 
“poor man” approach described in this study can reli-
ably provide an accurate alternative for liver iron deter-
mination for clinical application to monitor and guide 
management in patients with iron overload who require 
iron chelation therapy. 
Table 1. Bias, 95% Ci, and coefficient of variation of intra- and intersite observers of the r2* and tabulated hepatic iron concentration 
calculated from the measurable data range while coefficient of variations from all measurable data are presented in the parentheses.  
R2* Hepatic iron concentration 
Bias [95% CI] (Hz) Coefficient of variation (%) Bias [95% CI] (mg/g dw) Coefficient of variation (%)
  intrasite   0.39 [-9.64   10.44] 0.83 (1.31)  0.01 [-0.24 0.27] 0.80 (1.29)
  intersite  -4.72 [-23.38 13.93] 2.45 (4.46) -0.12 [-0.60 0.35] 2.20 (3.58)
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